Back to Search
ERIC SMALL, MD
MD
Internal Medicine Physician
NPI: 1437117454IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
G61618(CA)
Hematology (Internal Medicine) Physician
Internal Medicine — Hematology
Code: 207RH0000X
G61618(CA)
Medical Oncology Physician
Internal Medicine — Medical Oncology
Code: 207RX0202X
G61618(CA)
Education
CLVLND CLINIC LERNER COLLEGE OF MED OF CASE WSTN RSV UNIVERSITY
Class of 1985
Research & Publications (20)
A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.
PMID 17822457·BJU Int·2007
3-trial
Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.
PMID 17606721·Clin Cancer Res·2007
3-trial
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.
PMID 17363537·Clin Cancer Res·2007
3-trial
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
PMID 16809734·J Clin Oncol·2006
3-trial
Activities and accomplishments of the cancer and leukemia group B genitourinary committee.
PMID 16740791·Clin Cancer Res·2006
6-review
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
PMID 16690359·Mol Ther·2006
3-trial
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
PMID 15020604·J Clin Oncol·2004
3-trial
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
PMID 14581438·J Clin Oncol·2003
3-trial
Overview of bladder cancer trials in the Cancer and Leukemia Group B.
PMID 12673701·Cancer·2003
6-review
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
PMID 12177096·J Clin Oncol·2002
3-trial
Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response.
PMID 12063679·Semin Oncol·2002
6-review
Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer.
PMID 11685733·Semin Oncol·2001
3-trial
Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.
PMID 11230472·J Clin Oncol·2001
3-trial
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
PMID 11099318·J Clin Oncol·2000
3-trial
Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer.
PMID 11054432·J Clin Oncol·2000
3-trial
Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point.
PMID 10893284·J Clin Oncol·2000
3-trial
A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma.
PMID 10857997·Invest New Drugs·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1600 DIVISADERO ST
SAN FRANCISCO, CA 94115 - Phone
- (415) 353-7171
Quick Facts
- NPI
- 1437117454
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 41
- Publications
- 20
Are you this provider?
Claim Your Profile